Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Conditions
- Non-Small Cell Lung Carcinoma
- Advanced Non-Small Cell Squamous Lung Cancer
- EGFR Gene Mutation
Interventions
- DRUG: 89Zr-Patritumab deruxtecan
Sponsor
The Netherlands Cancer Institute
Collaborators